PRODUCTXPOVIO™

In July 2019, XPOVIO^TM (selinexor) received accelerated approval from the U.S. Food and Drug Administration for the treatment of heavily pretreated adult patients with relapsed or refractory multiple myeloma. In addition to the initial indication, selinexor is being studied in several additional clinical trials in various indications and combinations.

Background

In May 2024, Karyopharm entered into a series of financing transactions, including exchanging certain existing convertible debt, issuing a new senior term loan and repaying a portion of its Royalty Agreement with HCRx. As part of the series of transactions that occurred, HCRx purchased $15 million of a new Secured Term Loan, maturing in May 2028 and accruing interest at a rate of Secured Overnight Financing Rate (SOFR) plus 9.25%. HCRx also purchased $5 million of the newly issued 6.0% Convertible Notes due 2029. The collective series of financing transactions extended Karyopharm’s debt maturities into 2028 and 2029, well beyond its planned Phase 3 data readouts in 2025.